Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension
Mostra el registre complet Registre parcial de l'ítem
- dc.contributor.author Nikkho, Sylvia M.
- dc.contributor.author Richter, Manuel J.
- dc.contributor.author Shen, Eric
- dc.contributor.author Abman, Steven H.
- dc.contributor.author Antoniou, Katerina
- dc.contributor.author Chung, Jonathan
- dc.contributor.author Fernandes, Peter
- dc.contributor.author Hassoun, Paul
- dc.contributor.author Lazarus, Howard M.
- dc.contributor.author Olschewski, Horst
- dc.contributor.author Piccari, Lucilla
- dc.contributor.author Psotka, Mitchell
- dc.contributor.author Saggar, Rajan
- dc.contributor.author Shlobin, Oksana A.
- dc.contributor.author Stockbridge, Norman
- dc.contributor.author Vitulo, Patrizio
- dc.contributor.author Vizza, Carmine Dario
- dc.contributor.author Wort, Stephen John
- dc.contributor.author Nathan, Steven D.
- dc.date.accessioned 2023-02-13T07:14:25Z
- dc.date.available 2023-02-13T07:14:25Z
- dc.date.issued 2022
- dc.description.abstract Pulmonary hypertension (PH) has been linked to worse outcomes in chronic lung diseases. The presence of PH in the setting of underlying Interstitial Lung Disease (ILD) is strongly associated with decreased exercise and functional capacity, an increased risk of hospitalizations and death. Examining the scope of this issue and its impact on patients is the first step in trying to define a roadmap to facilitate and encourage future research in this area. The aim of our working group is to strengthen the communities understanding of PH due to lung diseases and to improve the care and quality of life of affected patients. This introductory statement provides a broad overview and lays the foundation for further in-depth papers on specific topics pertaining to PH-ILD.
- dc.format.mimetype application/pdf
- dc.identifier.citation Nikkho SM, Richter MJ, Shen E, Abman SH, Antoniou K, Chung J, Fernandes P, Hassoun P, Lazarus HM, Olschewski H, Piccari L, Psotka M, Saggar R, Shlobin OA, Stockbridge N, Vitulo P, Vizza CD, Wort SJ, Nathan SD. Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension. Pulm Circ. 2022 Jul 1;12(3):e12127. DOI: 10.1002/pul2.12127
- dc.identifier.doi http://dx.doi.org/10.1002/pul2.12127
- dc.identifier.issn 2045-8932
- dc.identifier.uri http://hdl.handle.net/10230/55725
- dc.language.iso eng
- dc.publisher Wiley
- dc.relation.ispartof Pulm Circ. 2022 Jul 1;12(3):e12127
- dc.rights © 2022 The Authors. Pulmonary Circulation published by John Wiley & Sons Ltd on behalf of Pulmonary Vascular Research Institute. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
- dc.rights.accessRights info:eu-repo/semantics/openAccess
- dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
- dc.subject.keyword Epidemiology
- dc.subject.keyword Interstitial lung disease
- dc.subject.keyword Prognosis
- dc.subject.keyword Pulmonary hypertension
- dc.subject.keyword Symptom assessment and management
- dc.title Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute's innovative drug development initiative-Group 3 pulmonary hypertension
- dc.type info:eu-repo/semantics/article
- dc.type.version info:eu-repo/semantics/publishedVersion